Business
SCYNEXIS to Present Clinical Data from Ongoing FURI and CARES Studies at the 10th Trends in Medical Mycology Meeting Showing Oral Ibrexafungerp Provides a Favorable Therapeutic Response in Patients with Severe Fungal Infections
Pre-clinical data on ibrexafungerp for mucormycosis also will be shared via an oral presentation JERSEY CITY, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) --
About this update from Scynexis, Inc.
[{"type":"text","content":"Pre-clinical data on ibrexafungerp for mucormycosis also will be shared via an oral presentation\nJERSEY CITY, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced two poster presentations of interim data from its ongoing FURI and CARES studies, evaluating oral ibrexafungerp for the treatment of patients with refractory mucocutaneous and invasive fungal infections will be presented at the 10th Trends in Medical Mycology (TIMM) meeting being held virtually and in-person in Aberdeen, Scotland, October 8-11, 2021. In addition, pre-clinical data on ibrexafungerp for the treatment of mucormycosis will be shared in an oral presentation. “There are limited oral options effective against multidrug-resistant pathogens in the hospital setting,” said David Angulo, M.D., Chief Medical Officer, SCYNEXIS. “We hope to address this unmet need by advancing oral ibrexafungerp through these studies. It is part of our ongoing commitment to patients in the hospital setting, who are battling invasive and sometimes fatal fungal infections.” Poster presentation details: Outcomes of Oral Ibrexafungerp by Pathogen from Two Open-label Studies of Patients with Serious Fungal Infections (FURI and CARES) – Riina Richardson, D.D.S., Ph.D., FRCPath, The University of Manchester, EnglandPoster #337Saturday, October 9, 20216 am – 7 am ET Oral Ibrexafungerp for Treatment of Patients with Refractory Mycoses: Interim Analysis of Outcomes from a Phase 3 Open-label Study (FURI) – Oliver A. Cornely, M.D., FECMM, FIDSA, FAAM, FACP, University of Cologne, GermanyPoster #336Sunday, October 10, 20216 am – 7 am ET Poster presentations will be accessible to meeting attendees via the TIMM program site. For more information on the Phase 3 FURI and CARES studies, visit ClinicalTrials.gov FURI (NCT03059992) and CARES (NCT03363841) Oral presentation details: Ibrexafungerp is effective in treating murine mucormycosis caused by Rhizopus delemar – Ashraf Ibrahim, Ph.D., FAAM, FECMM, an Investigator at The Lundquist Institute and Professor of Medicine, David Geffen School of Medicine, UCLASession: Symposium 16 Azoles, Echinocandins and Polyenes strengths and weaknessesSession #16.5 Sunday, October 10, 20219:15 am – 10:35 ...